Royalty Pharma plc (RPRX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
110 East 59th Street
New York, NY 10022
United States of America (the)
Phone
212 883 0200
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
100
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 44.02M | 1963 |
| Marshall Urist | Head of Research & Investments | 1.32M | 1976 |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | 1.32M | N/A |
| Christopher Hite | Chairman of Partnering & Investments | 1.32M | 1967 |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | 3.4M | 1970 |
| Arthur Richard McGivern | Executive Vice President of Investments & Chief Scientific Officer | 3.4M | 1975 |
| Molly Sawaya | Executive Vice President & Head of Human Capital | 0 | N/A |
| Sara Klymkowsky | Senior Vice President of Research & Investments | 0 | N/A |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications | 0 | N/A |
| Greg Butz | Executive Vice President of Partnering & Investments | 0 | N/A |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | 0 | N/A |
| Sandy Balkin | Senior Vice President of Strategy & Analytics | 0 | N/A |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.